In chemosensitive leukemias and solid tumors, anticancer drugs have been shown to induce apoptosis. Deficiencies in the apoptotic pathways may lead to chemoresistance. Here we report that glutathione (GSH) plays a critical role in activation of apoptosis pathways by CD95 (APO-1/Fas) or anticancer drugs. Upon treatment with anticancer drugs or CD95 triggering, CD95-resistant or Bcl-x L overexpressing CEM cells were deficient in activation of apoptosis pathways. CD95-resistant and Bcl-x L overexpressing CEM cells exhibited higher intracellular GSH levels in comparison to parental cells. Downregulation of GSH by L-buthionine-(S,R)-sulfoxime (BSO), a specific inhibitor of glutathione synthesis, reversed deficiencies in activation of apoptosis pathways by anticancer drugs or CD95. Interestingly, downregulation of GSH by BSO increased CD95 DISC formation in type I cells. In hybrids of CD95-resistant cells with sensitive cells and hybrids of overexpressing Bcl-x L cells with sensitive cells, the phenotype of apoptosis resistance was dominant. Also, in these hybrids, downregulation of GSH reversed CD95-and chemoresistance. We conclude that dominant apoptosis resistance depends, at least in part, on intracellular GSH levels, which may affect apoptosis signaling at different compartments, for example, the death receptor or mitochondria.
Introduction
A wide range of anticancer drugs, including chemotherapeutic agents, hormones, and various biologicals, induce apoptosis in malignant sensitive cells in vitro. 1, 2 Changes in the ability to activate the apoptotic machinery may play a role in drug resistance.
The CD95 cell surface receptor (CD95) is a member of the tumor necrosis factor/nerve growth factor (TNF/NGF) receptor superfamily of cell surface molecules which mediates apoptosis upon oligomerization. [3] [4] [5] [6] [7] [8] CD95 crosslinking by agonistic antibodies or the natural ligand initiates trimerization of CD95 and recruitment of adapter molecules Fas-associated death domain (FADD) and procaspase-8 to form the death-inducing signaling complex (DISC) , that leads to activation of caspases, which play a crucial role in apoptosis. 5 Apoptogenic caspases are divided into two classes, effector caspases and initiator caspases. Effector caspases are responsible for the cleavage that disassembles the cell, and initiator caspases initiate the proteolytic cascade. Caspase-3, -6, and -7 are the effector caspases and caspase-8 and -9 are the major initiator caspases.
The CD95 ligand (CD95-L) is a member of the corresponding family of TNF-related cytokines, which is found in a soluble or membrane-bound form. CD95-L may cause autocrine suicide in sensitive CD95
þ T cells and fratricide or paracrine death in neighboring T cells or other target cells. [9] [10] [11] Although a controversial issue, a number of studies have shown that activation of death receptor/ligand system such as the CD95 system may contribute to drug-induced apoptosis and altered death receptor signaling may play a role in chemoresistance. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In most cases, drug-mediated apoptosis was found to involve pertubations of mitochondrial functions. 15, [26] [27] [28] [29] Mitochondria-directed apoptotic stimuli induce a variety of mitochondrial changes such as the production of reactive oxygen species (ROS) and loss of mitochondrial membrane potential (DC m ). Disruption of DC m is mediated by opening of permeability transition (PT) pores, thereby releasing apoptogenic factors such as cytochrome c, apoptosis-inducing factor (AIF), caspase-2, and -9 from mitochondria into the cytosol triggering caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex. [30] [31] [32] [33] [34] [35] Caspase-9 activity can be inhibited by X-linked inhibitor-of-apoptosis protein (XIAP) by interacting with caspase-9. 36, 37 Mitochondria-related apoptosis is regulated by Bcl-2 family members, which are involved in the cellular response to a variety of apoptotic stimuli including chemotherapeutic agents. 38 Anticancer drugs were found to induce Bax expression 39 and overexpression of Bcl-2 or Bcl-x L has been shown to prevent apoptosis and to reduce pertubation of mitochondrial function and hyperproduction of ROS by different apoptosis inducing stimuli. cells, for example H9, SKW6.4, apoptosis is mediated by activation of caspase-8 at the CD95 DISC in large amounts, resulting in direct processing of caspase-3, a step which is independent of mitochondrial activation and cannot be blocked by Bcl-2. Alternatively, the mitochondrial apoptosis pathway is the preferred route in cells with reduced CD95 DISC formation (type II cells; for example, CEM, Jurkat) and mitochondria may function as amplifier in type II cells, activating both caspase-8 and -3. 43 In addition, signals originating from CD95 receptor may be linked to mitochondria by Bid, which assumes cytochrome-c-releasing activity upon cleavage by caspase-8. 44 After anticancer drug treatment, Bid was cleaved prior to mitochondrial alterations in type I cells providing a molecular link between caspase-8 activation and (secondary) mitochondrial pertubations, whereas in type II cells mitochondria act as an amplifier in caspase-8 activation and Bid was cleaved downstream of mitochondria. 44, 45 ROS play a critical role in apoptosis signaling. Reduced glutathione (GSH, a cystein-containing tripeptide), the most abundant intracellular thiol, acts as a major antioxidant by protecting against the damaging effects of free radicals and ROS and may protect cells from apoptotic cell death. [46] [47] [48] [49] GSH exists in all cells in nature and is the only available scavenger to hydrogen peroxide in mitochondria. Hydrogen peroxide is a precursor of hydroxyl radical through the participation of transition metals. ROS play a crucial role in apoptosis and the cellular redox state and mitochondriaderived ROS could modulate induction of CD95 ligand by anticancer drugs. 15, 50 Interestingly, caspase-8 activation at the DISC and DISC formation was found to be modulated by intracellular GSH levels in some systems. 51 Reduction of ROS by ROS scavenger was able to block apoptosis induced by TNF, anticancer drugs, g-irradiation, and activationinduced cell death in T cells (AICD). 52, 53 In this study, we investigated the role of intracellular GSH in determining apoptosis sensitivity and resistance in CD95-resistant cells, in Bcl-x L overexpressing cells, and in hybrids of apoptosis-sensitive and -resistant cells.
Results

Drug sensitivity of CD95-sensitive and -resistant cells
Resistance of tumor cells towards anticancer drug treatment may result from failure to activate apoptosis pathways. [12] [13] [14] [15] Previously, we found that CD95-resistant CEM cells generated by continuous long-term culture in agonistic antibody (anti-APO-1/anti-CD95) displayed cross-resistance to several anticancer drugs such as doxorubicin, etoposide, cytarabine, cisplatin, methotrexate, thioguanine, cyclophosphamide or vincristine (data not shown). [12] [13] [14] To see whether acquisition of cross-resistance to anticancer drugs parallels the development of CD95 resistance, we treated CEM cells by consecutive rounds of anti-CD95 treatment and compared those cells to long-term CD95-resistant cells (CEM CD95R-L ). We found that, concomitant with increased CD95 resistance, shortterm-treated CEM cells also gradually developed drug resistance ( Figure 1a ). In addition, caspase-3 and -9 activation, and XIAP and PARP cleavage were blocked (Figure 1b , c) and disruption of mitochondrial membrane potential (Figure 1d ) was significantly reduced after doxorubicin or CD95 treatment in short-and long-term CD95-resistant cells in comparison to parental cell lines. All experiments with doxorubicin also included other anticancer drugs to role out a drug-specific phenomenon (data not shown). This demonstrates that acquisition of death receptor resistance in these CEM cells is associated with resistance to other deathinducing stimuli.
Downregulation of GSH with BSO reversed resistance and deficient activation of apoptosis pathways by doxorubicin and CD95 in CD95-resistant cells and in overexpressing Bcl-x L cells
We and others have found that induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state and intracellular levels of GSH in chemoresistant tumor cells. 15, 50 . Therefore, we investigated whether apoptosis resistance and deficient activation of apoptosis pathways by CD95 or anticancer drugs in short-and long-term CD95-resistant cells were also influenced by intracellular GSH levels. In long-and short-term CD95-resistant cell lines, we found higher intracellular GSH levels in comparison to parental CEM cells (Figure 2a) . Concomitant with development of CD95 resistance and cross-resistance to anticancer drugs, upregulation of GSH levels was found in comparison to parental cell lines (Figure 2a) . Upregulation of intracellular GSH was most probably due to an increase in its synthesis, since downregulation of GSH by BSO (Figure 2a) , a specific inhibitor of glutathione synthesis, could reverse doxorubicin and CD95 resistance at a high nontoxic dose of BSO, sufficient to reduce GSH levels in these CD95-resistant cells (Figure 2a) . We used doses of BSO, which lowered the GSH content to values nearly the same as measured in sensitive CEM cells (Figure 2a ). If we used higher concentrations of BSO which further lowered the GSH content, the resistant cells died with BSO alone (data not shown). In addition, activation of caspase-3, PARP cleavage (Figure 2c) , and cytochrome c release from mitochondria (Figure 2d , e) after doxorubicin or CD95 treatment in CD95-resistant cells were restored after pretreatment with BSO. Furthermore, overexpression of Bcl-x L prevents cells from doxorubicin-and CD95-induced apoptosis and loss of DC m and ROS generation (data not shown).
40 Surprisingly, pretreatment of Bcl-x L overexpressing CEM cells (CEM Bcl-xL ) with the highest nontoxic dose of BSO also reversed defective doxorubicin-induced apoptosis (Figure 3a) , defective activation of caspase-3 (Figure 3b ), PARP cleavage (Figure 3b) , and cytochrome c release from mitochondria (Figure 3c, d ). Similar to previously published data, 58 reduction in the intracellular level of GSH by BSO resulted in downregulated expression of Bcl-x L protein in CEM Bcl-xL cells (Figure 3e ). These data demonstrate that intracellular GSH levels are critical for apoptosis resistance and defective activation of apoptosis pathways by doxorubicin or CD95 in CD95-resistant and in Bcl-x L overexpressing cells. 
Downregulation of GSH by BSO increases DISC formation depending on cell types
Previously, DISC formation and activation of caspase-8 at the DISC was found to be modulated by intracellular GSH levels and ROS generation. 51 The CD95 DISC contains several proteins including FADD and caspase-8 containing several cystein residues, which could be modified by GSH. 51 We therefore investigated if intracellular GSH levels could influence apoptosis signaling not only on mitochondria but also on DISC formation in our system ( Figure 4a ) leukemia cells were incubated with 1 mg/ml anti-APO-1 (a-APO-1) or 0.3 mg/ml doxorubicin (Doxo) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of anti-APO-1 (a-APO-1 þ BSO) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of doxorubicin (Doxo þ BSO) or left untreated (CONTROL) at 371C. Western blot analysis for caspase-3 and PARP was performed. The active fragment of caspase-3 was detected at B17 kDa and the cleaved product of PARP at B85 kDa. Equal protein loading was controlled by beta-actin. (d, e) Downregulation of intracellular GSH by BSO reversed deficient doxorubicin-and CD95-induced cytochrome c release in
) leukemia cells were incubated with anti-APO-1 (a-APO-1, black bars) or doxorubicin (black bars) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of anti-APO-1 (a-APO-1, white bars) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of doxorubicin (white bars) at 371C at concentrations as indicated. After 24 h, cytochrome c release was performed by FACScan analysis. Data are given as mean of triplicates with an S.D. of less than 10%. Similar results were obtained in three independent experiments. (e) CD95-resistant (CEM CD95R-L ) leukemia cells were incubated with 0.3 mg/ml doxorubicin (Doxo) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of doxorubicin (Doxo þ BSO) or left untreated (CONTROL) at 371C. After 48 h, cytochrome c release was performed by Western Blot analysis of cytosolic and mitochondrial fraction. Equal protein loading was controlled for the cytosolic fraction using beta-actin and for the mitochondrial fraction using Cox IV Figure 3 (a) BSO reversed deficient doxorubicin-induced apoptosis in Bcl-x L overexpressing leukemia cells (CEM Bcl-xL ). CEM Bcl-xL were incubated with doxorubicin (black bars) or preincubated for 12 h with 100 mg/ml BSO by addition of doxorubicin (white bars) at 371C at concentrations as indicated. After 48 h the percentage of apoptotic cells was measured by FSC/SSC. 55 Percentage of specific cell death was calculated as described in Figure 1a . Data are given as mean of triplicates with an S.D. of less than 10%. Similar results were obtained in three independent experiments. (b) BSO reversed deficient doxorubicin-induced caspase-3 activation and PARP cleavage in Bcl-x L overexpressing leukemia cells (CEM Bcl-xL ). CEM Bcl-xL were incubated 0.3 mg/ml doxorubicin (Doxo) or left untreated (CONTROL) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of doxorubicin (Doxo þ BSO) at 371C. After 72 h Western blot analysis for caspase-3 and PARP was performed. The active fragment of caspase-3 was detected at B17 kDa and the cleaved product of PARP at B85 kDa. Equal protein loading was controlled by beta-actin. were incubated with 0.3 mg/ml doxorubicin (Doxo) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of doxorubicin (Doxo þ BSO) or left untreated (CONTROL) at 371C. After 48 h, cytochrome c release was performed by Western Blot analysis of cytosolic and mitochondrial fraction. Equal protein loading was controlled for the cytosolic fraction using beta-actin and for the mitochondrial fraction using Cox IV. (e) Downregulation of Bcl-x L expression by BSO in Bcl-x L overexpressing leukemia cells (CEM Bcl-xL ). CEM Bcl-xL were incubated with 100 mg/ml BSO or left untreated (CONTROL) at 371C. After 72 h, Western blot analysis for Bclx L of whole-cell population (cell) and mitochondrial fraction (mitochondria) was performed. Bcl-x L was detected at B30 kDa. Equal protein loading was controlled for the whole-cell population using beta-actin and for the mitochondrial fraction using Cox IV induction of apoptosis was examined (Figure 4b ). In type I cells, H9 cells, increased recruitment of FADD and caspase-8 was found after preincubation with BSO in addition to CD95 triggering (Figure 4a ), indicating that an increased DISC formation was observed, which was associated with increased apoptosis induction (Figure 4b ). This suggests that apoptosis induction and signaling is affected at the level of the ) cells were incubated for 10 min with 1 mg/ml anti-CD95 (a-APO-1) or left untreated (CONTROL) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of anti-APO-1 (a-APO-1 þ BSO) at 371C. CD95 was immunoprecipitated. DISC preparation was performed. Detection of caspase-8 was performed using the mouse anti-caspase-8 monoclonal anitbody, which detects caspase-8 (p55) and the cleavage intermediates p43/p41. FADD was detected using an mouse anti-FADD monoclonal antibody and CD95 was immunodetected by an rabbit anti-CD95 polyclonal antibody serving as a control for precipitation efficacy and protein loading. , and Bcl-x L overexpressing leukemia cells (CEM Bcl-xL ) cells were incubated with 1 mg/ml anti-APO-1 (a-APO-1) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of anti-APO-1 (a-APO-1 þ BSO) at 371C. After 48 h, the percentage of apoptotic cells was measured by FSC/SSC in leukemia cells. 55 Data are given as mean of triplicates with an S.D. of less than 10%. Similar results were obtained in three independent experiments. Percentage of specific cell death was calculated as described in Figure 1a , and Bcl-x L overexpressing leukemia cells (CEM Bcl-xL ) cells were incubated with 1 mg/ml anti-APO-1 (a-APO-1) or left untreated (CONTROL) or preincubated for 12 h with 100 mg/ml BSO (BSO) by addition of anti-APO-1 (a-APO-1 þ BSO) at 371C. Western blot analysis for Bid was performed. Equal protein loading was controlled by beta-actin established concept of type I and type II cells established with these cells. 43, 44 Thus, restoration of CD95 sensitivity by BSO in resistant cells does not affect DISC formation. Interestingly, increased Bid cleavage was found after preincubation with BSO, followed by CD95 triggering (Figure 4c ), suggesting that Bid cleavage was associated with increased apoptosis induction (Figure 4b ).
Chemosensitivity of hybrids of apoptosis-resistant and -sensitive cells
In order to examine the efficacy of GSH-mediated apoptosis resistance, PEG-mediated cell fusion studies were performed with the chemosensitive B-cell line, SKW6, and the CD95-resistant T-cell line CEM CD95R-L (Figure 5a ). Hybrids and nonfused cells, present in the same mixture, could be identified by staining for different surface markers, and were treated with different anticancer drugs or APO-1 (CD95) antibody (Figure 5b ). Nonfused SKW6 cells remained sensitive and nonfused CEM CD95R-L remained resistant to anticancer drugs or CD95. However, hybrids of a sensitive cell and a CD95-resistant cell were as resistant to different anticancer drugs or CD95 as CD95-resistant single cells (Figure 5b ), indicating that resistance of CD95 was dominant in hybrids not only for doxorubicin but also for other anticancer drugs, which may induce apoptosis by different molecular mechanisms. In addition, hybrids of chemosensitive cells were as sensitive as the parental cell lines, indicating that the resistant phenotype is dominant (data not shown). Furthermore, caspase-3 activation was blocked (Figure 5c ) and disruption of mitochondrial membrane potential (Figure 5d ) and hyperproduction of ROS from mitochondria were significantly reduced in hybrids (Figure 5d ). Similar to single resistant cells, downregulation of GSH by BSO could reverse resistance in these hybrids (Figure 5e ).
We next studied whether Bcl-x L overexpressing hybrids could also be modulated by BSO. Hybrids of SKW6 with Bcl-x L overexpressing cells (CEM Bcl-xL ) found to be resistant to different anticancer drugs or CD95 similar to Bcl-x L overexpressing cells (Figure 5f ) and resistance could again be overcome by BSO treatment (Figure 5g ). These data demonstrate that CD95 resistance and anticancer drug resistance associated with CD95 resistance or Bcl-x L overexpression can be 'transferred' to produce resistance in hybrids, which can be modulated by the intracellular GSH levels.
Discussion
Deficiencies in apoptosis pathways may lead to resistance towards chemotherapy.
1,2,13,14 Here we report that resistance to apoptosis induced by both CD95 triggering or anticancer drugs, appears to depend on intracellular GSH levels which may affect apoptosis signaling in different compartments, at the level of the CD95 DISC or at the level of mitochondria, depending on different cell types (type I or type II cells).
Activation of caspases as effector molecules in response to death stimuli may be triggered by at least two different initiator compartments, the death receptor pathway or the mitochondrial pathway.
1 Defects in these pathways may lead to apoptosis resistance. To study the mechanisms of resistance and crossresistance in apoptosis pathways, we generated CD95-resistant CEM cells by consecutive rounds of anti-APO-1 (anti-CD95) treatment. Concomitant with increased CD95 resistance, these cells also gradually developed drug resistance and defects in apoptosis pathways, indicating that prolonged acquisition of death receptor resistance may be associated with resistance to other death pathways.
ROS have been implicated in both the initiation and execution of apoptosis, modulating apoptosis resistance. ROS are physiological metabolites, which may be generated from mitochondria. When ROS are produced in excessive amounts, mitochondria, nucleic acids, proteins, and lipids are extensively modified by oxidation. 59 To counteract the harmful consequence of ROS generation, mitochondria are equipped with MnSOD and redox cycle using reduced GSH and GSH peroxidase. 59 GSH is the most abundant intracellular thiol that functions in reduction of disulfid linkages of proteins and acts as an antioxidant. [46] [47] [48] [49] In addition, GSH is involved in modulation of induction of apoptosis and CD95 ligand by anticancer drugs in chemosensitive and anticancer drugresistant cells. 15, 50 We found that concomitant with development of CD95 resistance and anticancer drug cross-resistance intracellular GSH levels increased in resistant cells in comparison to parental sensitive cells. Downregulation of intracellular GSH levels by BSO, a specific inhibitor of glutathione synthesis, restored doxorubicin-as well as CD95-induced apoptosis and reversed deficient caspase activation and deficient mitochondrial activation (downregulation of mitochondrial membrane potential, hyperproduction of ROS and release of cytochrome c from mitochondria) after doxorubicin treatment or CD95 triggering in CD95-resistant CEM cells. In addition, we found that also in Bcl-x L overexpressing CEM cells resistant to doxorubicin and CD95 downregulation of GSH by BSO reversed deficient activation of caspases and mitochondria by doxorubicin treatment or CD95 triggering. These data suggest that GSH affects apoptosis sensitivity at different levels.
Recently, CD95 DISC formation and activation of caspase-8 at the DISC was found to depend on intracellular GSH levels and ROS generation in SKW6. 4 . 51 In different cell types, apoptosis is initiated either by activation of large amounts of caspase-8 at the CD95 DISC followed by rapid cleavage of caspase-3 (type I cells, for example, SKW 6.4, H9) or the mitochondrial apoptosis pathway is the preferred route as a result of reduced CD95 DISC formation in those cells (type II, for example, Jurkat, CEM) and mitochondria may function as an amplifier, activating both caspase-8 and -3. [43] [44] [45] In H9 cells (type I cells), we observed an increased CD95 DISC formation after downregulation of intracellular GSH levels by BSO associated with increased apoptosis induction, increased caspase-8 activation followed by Bid cleavage, indicating that apoptosis signaling was affected downstream of the CD95 DISC in this cell type. However, in CD95-resistant CEM cells (type II cells) and in Bcl-x L overexpressing CEM cells (type II cells) as well as in the parental sensitive CEM cells (type II cells), only a slight CD95 DISC formation after coincubation of anti-APO-1 with BSO was found, suggesting that GSH does not define the type I or type II phenotype. Interestingly, Bid cleavage was found after preincubation with BSO following CD95 treatment in CD95-resistant CEM cells and in Bcl-x L overexpressing CEM cells, suggesting that Bid cleavage was associated with increased caspase-8 activation and increased apoptosis induction downstream of mitochondria. Since downregulation of GSH could reverse deficient activation of mitochondria in CD95-resistant CEM cells and in Bcl-x L overexpressing CEM cells, GSH in type II cells appears to affect apoptosis signaling predominantly at the mitochondrial level.
Only few cell fusion studies have been performed addressing the mechanisms of drug resistance. 60 Fusion of etoposide-sensitive cells with etoposide-resistant cells revealed a dominant resistance or an intermediate sensitivity of hybrids. 58 We found that hybrids of CD95-resistant cells with chemosensitive cells produced the resistant response after anticancer drug treatment or CD95 triggering. Activation of 43, 44 In hybrids of Bcl-x L overexpressing CEM (type II) and SKW6 (type I) cells, Bcl-x L could block CD95-and anticancer drug-induced apoptosis, indicating that Bcl-x L -mediated resistance is dominant in hybrids also in type I cells. Interestingly, downregulation of intracellular GSH levels by BSO also reversed deficient anticancer drug-and CD95-induced apoptosis in Bcl-x L blocked type I/type II hybrids, indicating that GSH-mediated resistance of individual cells is also responsible for the 'transferred resistance' in hybrids.
Taken together, our data suggest that dominant CD95 resistance and anticancer drug resistance of CD95-resistant CEM cells or Bcl-x L overexpressing CEM cells associated with deficient activation of apoptosis pathways depend, at least in part, on intracellular GSH levels, which could affect apoptosis signaling in different compartments at the level of the death receptor or at the level of the mitochondria. Modulation of intracellular GSH levels may restore apoptosis sensitivity in previously resistant cells.
Materials and Methods
Cell lines and culture conditions
, H9) and leukemia B cells (SKW6) were grown in RPMI 1640 (GIBCO BRL Eggenstein, Germany) containing 10% fetal calf serum (Conco, Wiesbaden, Germany), 10 mM HEPES, pH 7.3 (Biochrom, Berlin, Germany), 100 U/ml penicillin (GIBCO), 100 mg/ml streptomycin (GIBCO), and 2 mM L-glutamine (Biochrom). CEM CD95R-L , a variant of CEM resistant towards anti-APO-1 (anti-CD95) up to 1 mg/ml, was generated by continuous culture in anti-APO-1 for more than 12 months 12,13 (long-term CD95-resistant cells). To preserve the resistance of these cell line, CEM CD95R-L was treated every 2 weeks with anti-APO-1 (anti-CD95 were resistant towards anti-APO-1 (anti-CD95) up to 1 mg/ml, but would not proliferate by continuous culture in anti-APO-1 (anti-CD95) for a long period of time. After eight rounds of treatment of CEM (CEM
CD95RÀ8
) with anti-APO-1 (anti-CD95), CEM CD95RÀ8 were resistant towards anti-APO-1 (anti-CD95) up to 1 mg/ml and can proliferate by continuous culture in anti-APO-1 (anti-CD95). These generated CD95-resistant (CEM CD95RÀ8 , short-term) cells were used for further experiments and for anticancer treatment. CEM NEO and CEM Bcl-xL were generated and cultured as described by Scaffidi et al. 43 All cell lines were mycoplasma free.
Drugs and reagents
Doxorubicin (Doxo, Farmitalia, Milano, Italy), cytarabine (AraC) (Pfizer, Karlsruhe, Germany), cisplatin (Sigma Deisenhofen, Germany), cyclophosphamide (4-hydroperoxy-cyclophosphamide) (Baxter Oncology, Frankfurt, Germany), and vincristine (Bristol, Regensburg, Germany) were freshly dissolved in sterile distilled water, methotrexate (Whyet Pharma, Münster, Germany) was freshly dissolved in steril 0.01 N NaOH, thioguanine (Deutsche Welcome, Burgwedel, Germany) and etoposide (Alexis, Grünberg, Germany) were freshly dissolved in sterile 0.05 vol% DMSO, prior to each experiment to ensure constant quality of the preparations. All anticancer drugs were provided by the manufacturers as pure substances. L-buthionine-(S,R)-sulfoximine (BSO) (Sigma, Deisenhofen, Germany) was freshly dissolved in sterile distilled water prior to each experiment to ensure constant quality of the preparations. Anti-APO-1 (anti-CD95) used for stimulation of cells and for the DISC were generated as described. 54 
Induction of apoptosis
For quantitative determination of apoptosis, cells were lysed in Nicoletti buffer (0.1% sodium citrate plus 0.1% Triton X-100 (Sigma)) containing propidium iodide (50 mg/ml) as described. 55 Propidium iodide-stained nuclei 55 or forward scatter/side scatter (FSC/SSC) profile of cells 56 were analyzed by flow cytometry (FACScan, Becton Dickinson, Heidelberg, Germany).
Cytofluorometric analysis of mitochondrial transmembrane potential (DW m ) and ROS generation
To measure DC m and ROS generation, cells (5 Â 10 5 /ml) were incubated with 3,3 0 -dihexyloxacarbocyanine iodide (DiOC 6 (3), 460 ng/ml; FL-1) (Moleculare Probes, Inc.,. Eugene, OR, USA) for DC m and dihydroethidine (HE, 126 ng/ml, FL-3) (Moleculare Probes) for ROS generation for 12 min at 371C in the dark followed by analysis on a flow cytometer (FACScan).
Analysis of reduced glutathione (GSH)
Measurement of intracellular GSH (reduced glutathione, GSH) was done with the manufactory instructions of the Glutathione Assay Kit from Calbiochem (Calbiochem-Novabiochem Corporation, San Diego, CA, USA). The concentrations of GSH were calculated from a titration curve established using known concentrations of purified GSH and indicated in nM concentration (Sigma) .
Western blot analysis
Proteins were extracted from cells lysed for 30 min at 41C in PBS with 0.5% Triton X (Serva, Heidelberg, Germany) and 1 mM PMSF (Sigma), followed by high-speed centrifugation. Protein concentration was assayed using bicinchoninic acid (Pierce, Rockford, USA). In all, 100 mg protein per lane was separated by 10-20% SDS-PAGE and electroblotted to nitrocellulose (Amersham, Braunschweig, Germany). After blocking for 1 h in PBS supplemented with 5% milk powder (Sigma) and 0.1% Tween 20 (Sigma) , immunodetection of PARP, caspase-3, active caspase-3, caspase-9, XIAP, Bcl-x L , Bid, and b-actin was done using rabbit anti-PARP polyclonal antibody (1 : 5000, Enzyme Systems Products, Dublin, CA, USA), mouse anti-caspase-3 monoclonal antibody (1 : 500, Transduction Laboratories), rabbit anti-active-caspase-3 polyclonal antibody (1 : 200, Chemicon International, Temecula, CA, USA), rabbit anticaspase-9 polyclonal antibody (1 : 5000, Transduction Laboratories), mouse anti-XIAP monoclonal antibody (anti-hILP, 1 : 1000, Transduction Laboratories), rabbit anti-Bcl-x S/L polyclonal antibody (1:1000, Santa Cruz, CA, USA), rabbit anti-Bid polyclonal antibody (1 : 1000, R&D Systems
